Released Her2
Released Her2 - Related Videos
10:21
Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation
0 Views •
Cited by 3 •
2017
Fluorescence in-situ hybridization (FISH) is often required in combination with histopathology and molecular diagnostics for selection of therapy in personalized medicine. A novel non-cross-linking, formalin-free tissue fixative that allows high quality morphologic, molecular and FISH analyses from the same specimen by addition of a post-fixation step before FISH is presented.
11:52
Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
0 Views •
Cited by 1 •
2013
This article details the procedures for optical imaging analysis of the tumor-targeted nanoparticle, HerDox. In particular, detailed use of the multimode imaging device for detecting tumor targeting and assessing tumor penetration is described here.
01:28
Energy-releasing Steps of Glycolysis
0 Views •
2019
Glycolysis is divided into two phases based on whether energy is utilized or released. While the first phase consumes ATP, the second phase produces energy in the form of ATP and NADH. The energy is released over a sequence of reactions that turns G3P into pyruvate. The energy-releasing phase—steps 6-10 of glycolysis—occurs twice, once for each of the two 3-carbon sugars produced during steps 1-5 of the first phase. The first energy-releasing step—the 6th step of glycolysis —consists of two...
01:22
Modified-Release Drug Delivery Systems: Drug Release Characteristics
0 Views •
2026
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
01:25
Inhibitors Of Virion Release
0 Views •
2026
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
FAQs
Proteolytic cleavage can produce two biologically relevant outcomes: the extracellular region enters surrounding fluid, while a receptor fragment remains associated with the cancer-cell membrane. That remaining fragment may continue signaling through pathways linked to cell proliferation and survival. Consequently, extracellular HER2 measurements can reflect cleavage while the membrane-associated fragment may retain functional relevance for tumor behavior.
The membrane-retained fragment matters because release of the extracellular region does not necessarily eliminate HER2-related signaling. The remaining receptor portion may continue activating pathways that support cancer-cell proliferation and survival. Studying both the released material and the residual receptor therefore helps researchers connect soluble biomarker findings with the signaling behavior of tumor cells.
Interpretation depends strongly on assay design and clinical context. An assay must be considered in relation to what form of HER2 it detects, while the biological setting determines how a measured signal relates to tumor behavior. For this reason, a soluble HER2 result is most informative when evaluated alongside the relevant tumor model, disease context, or treatment question.
Researchers measure soluble HER2 in blood and in tumor models to investigate release from cancer cells and its relationship to tumor biology. These settings provide complementary information: blood supports biomarker-oriented analysis, whereas tumor models allow the release process and associated signaling behavior to be studied in a cancer research system. The resulting data can guide further mechanistic or translational studies.
Changes in soluble HER2 can be investigated as biomarker information during studies of treatment response. Researchers compare measurements with the relevant clinical or experimental treatment context rather than interpreting the value in isolation. This approach may help assess how tumor biology changes during therapy, while assay characteristics and context remain essential for deciding what a measured change means.
Soluble HER2 measurements can contribute to research on why tumors respond differently or develop resistance to HER2-targeted therapies. Investigators can examine released HER2 alongside the signaling capacity of the remaining receptor fragment, linking extracellular measurements with pathways that promote proliferation and survival. This combined perspective supports studies of resistance mechanisms without treating the soluble signal as a complete explanation by itself.